Prelude Therapeutics Inc PRLD
Prelude Therapeutics Incorporated ("Prelude" or the "Company") is a precision oncology company built on a foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients. By leveraging our core competencies in cancer biology and medicinal chemistry, combined with our clinical development capabilities, we have built an efficient, drug discovery engine and the development expertise necessary to identify compelling biological targets and create new chemical entities, or NCEs, that we advance into clinical trials. We believe our approach could result in better targeted cancer therapies. Our discovery excellence has been supported by our steady progress in advancing a pipeline of novel precision oncology development candidates, alone and with partners. We are working with our partner AbCellera Biologics, Inc. ("AbCellera") on an early-stage discovery program involving potent degraders as payloads for novel antibodies targeting tumor specific antigens. Since our inception in 2016, we have received clearance from the U.S. Food and Drug Administration, or the FDA, for multiple investigational new drug applications, or INDs, and successfully advanced several programs into clinical trials. In addition, we have other differentiated proprietary programs in various stages of preclinical development.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.1M | $7.0M | — | — | — | — | — | — |
| R&D | $94.3M | $118.0M | $103.4M | $92.9M | $86.8M | $48.2M | $24.3M | — |
| SG&A | $22.4M | $28.7M | $28.9M | $30.7M | $27.0M | $10.6M | $3.8M | — |
| Total operating expenses | $116.7M | $146.7M | $132.3M | $123.5M | $113.7M | $58.8M | $28.1M | — |
| Operating income | -$104.6M | -$139.7M | -$132.3M | -$123.5M | -$113.7M | -$58.8M | -$28.1M | — |
| Pre-tax income | -$99.5M | -$127.2M | — | — | — | — | — | — |
| Income tax | $0 | $0 | — | — | — | — | — | — |
| Net income | -$99.5M | -$127.2M | -$121.8M | -$115.4M | -$111.7M | -$56.9M | -$27.6M | — |
| EPS, basic | -1.29 | -1.68 | -2.02 | -2.44 | -2.43 | — | — | — |
| EPS, diluted | -1.29 | -1.68 | -2.02 | -2.44 | -2.43 | -4.56 | -16.52 | — |
| Shares, diluted (wtd. avg.) | 77.0M | 75.8M | 60.4M | 47.4M | 46.0M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $35.3M | $12.5M | $25.3M | $30.6M | $31.8M | $218.3M | $18.9M | — |
| Short-term investments | $68.0M | $121.1M | $207.6M | $171.1M | $259.4M | — | — | — |
| Total current assets | $105.7M | $135.9M | $235.6M | $204.4M | $295.1M | $220.8M | $20.2M | — |
| Property, plant and equipment | $5.1M | $6.8M | $7.3M | $4.9M | $3.9M | $2.5M | $1.6M | — |
| Total assets | $141.3M | $175.5M | $277.7M | $220.5M | $305.1M | $223.6M | $21.9M | — |
| Accounts payable | $4.0M | $7.7M | $4.6M | $6.8M | $7.8M | $3.9M | $2.0M | — |
| Total current liabilities | $53.0M | $25.6M | $21.8M | $21.7M | $19.2M | $11.4M | $4.8M | — |
| Total liabilities | $72.7M | $44.1M | $40.6M | $25.1M | $19.2M | $11.4M | $4.8M | — |
| Retained earnings | -$683.1M | -$583.6M | -$456.4M | -$334.6M | -$219.1M | -$107.4M | -$50.5M | — |
| Total equity | $68.6M | $131.5M | $237.1M | $195.4M | $285.9M | $212.2M | -$49.4M | -$22.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$56.3M | -$102.9M | -$107.1M | -$83.7M | -$83.5M | -$46.2M | -$25.7M | — |
| Depreciation and amortisation | $1.7M | $1.8M | $1.2M | $1.3M | $915.0K | $542.0K | $382.0K | — |
| Stock-based compensation | $11.9M | $21.3M | $25.6M | $25.1M | $20.9M | $5.6M | $846.0K | — |
| Capital expenditure | $67.0K | $764.0K | $3.5M | $3.0M | $2.3M | $621.0K | $780.0K | — |
| Investing cash flow | $53.5M | $90.2M | -$34.6M | $81.7M | -$263.8M | -$621.0K | -$780.0K | — |
| Financing cash flow | $24.8M | -$120.0K | $136.4M | $815.0K | $164.9M | $246.2M | $29.7M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-191532.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $7.0M | $12.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$27.6M | -$56.9M | -$111.7M | -$115.4M | -$121.8M | -$127.2M | -$99.5M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |